Loxo Oncology Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Loxo Oncology (LOXO) PT Lowered to $185 at Oppenheimer
November 8, 2018 10:51 AM ESTOppenheimer analyst Leah Rush Cann lowered the price target on Loxo Oncology (NASDAQ: LOXO) to $185.00 (from $202.00) while maintaining a Outperform rating.
Cann commented, "Loxo's lower than estimated 3Q18 loss resulted from net collaboration revenue recognition of $42.5 million. This, in turn, arose from $52.9 million in... More
Loxo Oncology (LOXO) Reports Q3 Loss of $2.26/Share
November 8, 2018 6:50 AM ESTLoxo Oncology (NASDAQ: LOXO) reported Q3 EPS of ($2.26), versus ($0.94) reported last year. Revenue for the quarter came in at $42.5 million, versus $0 reported last year.
For earnings history and earnings-related data on Loxo Oncology (LOXO) click here.
... More